At a glance
ClinicalIndex Comparison RecordPhase 2Terminated· 5 enrolled
Drug / intervention
Ixazomibdrug
Likely dose
Ixazomib 4 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase II Study Of Ixazomib As Maintenance Therapy For Patients With Acute Myeloid Leukemia (AML) And High Risk Myelodysplastic Syndrome (MDS) In Remission
In Brief
A Phase 2 clinical trial evaluating Ixazomib for Leukemia. Terminated early, enrolled 5 participants across 1 site.
Signals
Trial was terminated early
Detailed Summary
The goal of this clinical research study is to learn if ixazomib can prevent AML or MDS from coming back in patients who are in remission. The safety of this drug will also be studied.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsLeukemia
CountriesUnited States
CollaboratorsMillennium: The Takeda Oncology Company
Timeline
Phase 2TerminatedFinished
201520162017201820192020202120222023202420252026
First PostedNov 2014
Enrollment StartMar 2015
Primary CompletionMay 2017
TodayJul 2026
First PostedNov 27, 2014
Enrollment StartMar 20, 2015
Primary CompletionMay 30, 2017
TodayJul 1, 2026
Enrollment to primary: 2.2 yearsPosted 11.6 years ago
Interventions
Ixazomibdrug
4 mg by mouth on Days 1, 8 and 15 of each 28-day cycle.